Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935861 | 1.00 | MAPT (0.70) | MAPTRAB9AGAANPC1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2984718 | 0.98 | MAPT (0.68) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL10055019 | 0.91 | MAPT (0.82) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL1844199 | 0.91 | MAPT (0.82) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL5669873 | 0.91 | MAPT (0.82) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL18434613 | 0.86 | MAPT (0.70) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL22783768 | 0.85 | MAPT (0.74) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL455536 | 0.84 | MEN1 (0.50) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL5154356 | 0.84 | MEN1 (0.50) | MAPTRAB9AGAANPC1L3MBTL1 | |
| SCHEMBL3422016 | 0.84 | MEN1 (0.50) | MAPTRAB9AGAANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41549-E1 | Dyes for keratin fibers, the dyes containing n-benzyl-p-phenylenediamine derivatives and novel n-benzyl-p-phenylenediamine derivatives | WELLA AG (DE) | 2010-08-24 | — | — | US | claimed |
| EP-1226107-B1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | WELLA AG (DE) | 2005-10-05 | — | — | EP | claimed |
| US-6689174-B2 | FOR OXIDATIVELY DYEING HUMAN HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 2004-02-10 | — | — | US | claimed |
| US-20020166181-A1 | N-benzyl-p-phenylenediamine-derivatives containing colouring agents for keratin fibres and novel n-benzyl-p-phenylenediamine-derivatives | CHASSOT LAURENT (CH) | 2002-11-14 | — | — | US | claimed |
| EP-1226107-A1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | Wella Aktiengesellschaft (DE) | 2002-07-31 | — | — | EP | claimed |
| WO-2002018318-A1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-03-07 | — | — | WO | claimed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1379507-B1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-RE41549-E1 | Dyes for keratin fibers, the dyes containing n-benzyl-p-phenylenediamine derivatives and novel n-benzyl-p-phenylenediamine derivatives | WELLA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1379505-B1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER HEALTHCARE LLC | 2006-01-26 | — | — | US | disclosed |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION | 2003-11-06 | — | — | US | disclosed |
| US-20020166181-A1 | N-benzyl-p-phenylenediamine-derivatives containing colouring agents for keratin fibres and novel n-benzyl-p-phenylenediamine-derivatives | CHASSOT LAURENT (CH) | 2002-11-14 | — | — | US | disclosed |
| WO-2002085859-A1 | HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085857-A2 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1226107-A1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | Wella Aktiengesellschaft (DE) | 2002-07-31 | — | — | EP | disclosed |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | BAYER CORPORATION | 2002-05-30 | — | — | US | disclosed |
| WO-2002018318-A1 | N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES CONTAINING COLOURING AGENTS FOR KERATIN FIBRES AND NOVEL N-BENZYL-P-PHENYLENEDIAMINE-DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BRAF, RAF1, ARAF | MAPT 908/4885RAB9A 558/4885GAA 2983/4885 |
| US-20060019990-A1 | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas | BRAF, RAF1, ARAF | MAPT 938/4885RAB9A 574/4885GAA 3020/4885 |
| US-20030207914-A1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BRAF, RAF1, ARAF | MAPT 908/4885RAB9A 558/4885GAA 2983/4885 |
| US-20020065296-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | MAPK1, MAP3K1, MAPK3 | MAPT 150/4885RAB9A 1159/4885GAA 3052/4885 |
| US-20020166181-A1 | N-benzyl-p-phenylenediamine-derivatives containing colouring agents for keratin fibres and novel n-benzyl-p-phenylenediamine-derivatives | KRT18, KPNB1, VIM | MAPT 725/4885RAB9A 2646/4885GAA 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.